Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)47.77bn
- Net income in JPY17.11bn
- Incorporated2006
- Employees603.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keymed Biosciences Inc | 1.74bn | -15.85bn | 219.40bn | 1.12k | -- | 3.90 | -- | 125.98 | -3.05 | -3.05 | 0.3355 | 10.13 | 0.0207 | 0.3115 | 7.74 | 97,782.76 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 19.26bn | -7.68bn | 265.37bn | 574.00 | -- | 16.21 | -- | 13.78 | -1.34 | -1.34 | 3.33 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,663,856.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| InnoCare Pharma Ltd | 19.19bn | -8.02bn | 271.81bn | 1.09k | -- | 3.55 | -- | 14.16 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| Joinn Laboratories China Co Ltd | 45.36bn | -19.49m | 276.92bn | 2.59k | -- | 1.76 | -- | 6.10 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| Peptidream Inc | 47.77bn | 17.11bn | 333.28bn | 603.00 | 19.44 | 5.68 | 17.17 | 6.98 | 131.84 | 131.84 | 368.46 | 451.11 | 0.5989 | 4.41 | 6.17 | 79,224,840.00 | 21.46 | -- | 26.08 | -- | 74.37 | -- | 35.83 | -- | 3.34 | 44.62 | 0.2575 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| RemeGen Co Ltd | 32.51bn | -33.14bn | 346.95bn | 3.62k | -- | 8.46 | -- | 10.67 | -2.88 | -2.88 | 2.83 | 4.35 | 0.2712 | 0.4446 | 5.00 | 421,122.40 | -27.65 | -18.66 | -36.21 | -23.69 | 78.65 | 81.64 | -101.95 | -102.21 | 0.9558 | -32.19 | 0.5167 | -- | 40.26 | 141.16 | -51.30 | -- | 59.07 | -- |
| Sinocelltech Group Ltd | 52.21bn | -526.12m | 378.55bn | 2.33k | -- | -- | -- | 7.25 | -0.0553 | -0.0553 | 5.49 | -0.2874 | 0.8146 | 0.4624 | 5.26 | 1,048,041.00 | -0.8674 | -40.17 | -2.70 | -74.63 | 95.83 | 95.42 | -1.06 | -108.20 | 0.588 | 5.45 | 1.05 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Dizal Pharmaceutical Co Ltd | 8.32bn | -17.88bn | 425.20bn | 581.00 | -- | 46.48 | -- | 51.11 | -2.04 | -2.04 | 0.9471 | 1.03 | 0.235 | 0.4033 | 6.15 | 670,632.10 | -56.00 | -46.02 | -83.89 | -52.99 | 97.17 | 57.53 | -238.28 | -2,081.54 | 1.66 | -193.39 | 0.674 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Genscript Biotech Corp | 156.03bn | -27.36bn | 448.11bn | 7.28k | -- | 2.38 | -- | 2.87 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,786.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
Data as of Nov 22 2024. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
34.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 30 Aug 2024 | 9.74m | 7.49% |
| Taiyo Pacific Partners LPas of 29 Oct 2024 | 8.03m | 6.18% |
| Asset Management One Co., Ltd.as of 13 Sep 2024 | 5.90m | 4.54% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 14 Jul 2023 | 4.44m | 3.42% |
| Baillie Gifford & Co.as of 31 Oct 2024 | 3.87m | 2.98% |
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 3.25m | 2.50% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 3.01m | 2.31% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.84m | 2.19% |
| Nikko Asset Management Co., Ltd.as of 14 Jul 2023 | 1.80m | 1.39% |
| Alma Capital Investment Management SA (UK)as of 30 Jun 2024 | 1.60m | 1.23% |
More ▼
Data from 30 Jun 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
